Cargando…
Structural Approach to Assessing the Innovativeness of New Drugs Finds Accelerating Rate of Innovation
[Image: see text] Measuring innovation in the pharmaceutical industry is challenging. Counts of new molecular entities (NMEs) approved by the Food and Drug Administration (FDA) are commonly used, but this measure only gauges quantity not innovativeness. A new indicator of innovation for small molecu...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical
Society
2020
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667644/ https://www.ncbi.nlm.nih.gov/pubmed/33209190 http://dx.doi.org/10.1021/acsmedchemlett.0c00319 |